February 16, 2024
Chugai Pharmaceutical said on February 15 that it has submitted an application to Japanese regulatory authorities seeking a label expansion of its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). The Roche group company made the filing the same day...read more